Myriad Genetics (MYGN) reported $825M in revenue for fiscal 2025, −1.6% year on year. That ranks #1901 by revenue among 2853 SEC filers and #176 in Healthcare. It posted a net loss of −$366M for the same year. Revenue has grown 5.3% a year on average since 2011 ($402M then). The fiscal 2025 balance sheet shows $707M in total assets, $150M in cash and $120M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $825M | −1.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $577M | −1.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$387M | −$264M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$366M | −$239M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.8M | +$10.5M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $45.3M | +151.7% | FY20222022-12-31 |
| Total assetsAssets | $707M | −31.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $368M | −47.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $150M | +46.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $120M | +202.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $200M | −$34.1M | Open → |
| Q2 20262026-06-30 | $191M | −$43.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Myriad Genetics Inc
- Ticker
- MYGN
- Exchange
- Nasdaq
- SIC classification
- In Vitro & In Vivo Diagnostic Substances (2835)
- Fiscal year end
- 12-31
- CIK
- 0000899923
Filings
- 10-QJul 31, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Harmony BiosciencesHRMY | $868M | $159M |
| Innovage HoldingINNV | $854M | −$30.3M |
| Arrowhead PharmaceuticalsARWR | $829M | −$1.6M |
| Myriad GeneticsMYGN | $825M | −$366M |
| Orthofix MedicalOFIX | $822M | −$92.2M |
| Ascendis PharmaASND | $814M | −$258M |
| Caris Life SciencesCAI | $812M | −$68.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Myriad Genetics — Key figures |url=https://companiesranked.com/en/company/myriad-genetics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Myriad Genetics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/myriad-geneticsBibTeX
@misc{companiesranked-en-company-myriad-genetics-2026,
author = {{CompaniesRanked}},
title = {{Myriad Genetics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/myriad-genetics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000899923-26-000018 · February 24, 2026
{{cite web |title=Myriad Genetics — Key figures — 10-K (0000899923-26-000018) |url=https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.